Litcius/Paper detail

Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance

Sarju Ganatra, Ana Barac, Saro H. Armenian, Christine Cambareri, Crystal S. Denlinger, Susan Dent, Salim S. Hayek, Bonnie Ky, Monika Leja, Claire Huang Lucas, Bhargav Makwana, Nicolas L. Palaskas, Jacqueline B. Vo

2025Journal of the American College of Cardiology10 citationsDOI

Topics & Concepts

MedicineAdverse effectImmune systemInternal medicineOncologyVascular endothelial growth factorGrowth factorImmunotherapyTyrosine-kinase inhibitorAngiogenesisImmunologyVascular endothelial growth factor ATargeted therapyVEGF receptorsEndotheliumTyrosineCancer researchChemotherapy-induced cardiotoxicity and mitigationCancer Immunotherapy and BiomarkersChronic Lymphocytic Leukemia Research
Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance | Litcius